CX5461 CAS:1138549-36-6

CAS NO: 1138549-36-6
CX5461 CAS:1138549-36-6
Description Review
Description

RNA Polymerase I Inhibitor II CX-5461 CAS: 1138549-36-6 is a relatively new drug that has been gaining attention in the medical field for its potential to treat certain types of cancer. This article will explore the properties and effects of this medication and provide information about its potential benefits and risks.

Introduction

RNA Polymerase I Inhibitor II CX-5461 CAS: 1138549-36-6, commonly known as CX-5461, is a small molecule that is being studied as a potential cancer therapy. It is a selective inhibitor of RNA polymerase I, an enzyme that is involved in the synthesis of ribosomal RNA. CX-5461 has shown promising results in preclinical studies and is currently undergoing clinical trials.

Chemical Properties

The chemical name of CX-5461 is (4-(4-methylpiperazin-1-yl)-6-nitro-benzo[d]thiazol-2-yl)-(5-(piperazine-1-carbonyl)pyridin-2-yl)amine. Its molecular formula is C22H27N7O2S and its formula weight is 469.57 g/mol. The CAS number for CX-5461 is 1138549-36-6.

Top Ten Keywords

  1. CX-5461 mechanism of action
  2. CX-5461 preclinical studies
  3. CX-5461 clinical trials
  4. CX-5461 toxicity
  5. CX-5461 pharmacokinetics
  6. CX-5461 side effects
  7. CX-5461 dosing
  8. synthetic lethality CX-5461
  9. CX-5461 ribosomal RNA
  10. CX-5461 cancer treatment

Synonyms

CX-5461 is also known by the following synonyms:

  • (4-(4-Methylpiperazin-1-yl)-6-nitro-[1,3]benzothiazol-2-yl)-{5-[(1-piperazinylcarbonyl)amino]-2-pyridinyl}amine
  • CX5461
  • UNII-Q888Z6UW8L
  • ZINC70211019

Health Benefits

CX-5461 has shown potential as a cancer treatment, particularly for certain types of tumors that have mutations in the p53 gene. This is because CX-5461 has been shown to disrupt the cancer cells' ability to synthesize ribosomal RNA, which is necessary for their growth and survival. CX-5461 has shown promising results in preclinical studies and is currently undergoing clinical trials for the treatment of solid tumors and hematological malignancies.

Potential Effects

CX-5461 has been shown to have anticancer effects in preclinical studies, but it is important to note that these studies have been conducted on animals and in vitro, and the results may not necessarily translate to humans. CX-5461 is being studied specifically for its ability to inhibit RNA polymerase I, which is overexpressed in many types of cancer cells. By inhibiting this enzyme, CX-5461 disrupts the cancer cells' ability to synthesize ribosomal RNA, leading to their death. Additionally, CX-5461 has been shown to induce synthetic lethality in cells with a mutated p53 gene, which may make it an effective treatment for cancers that harbor this mutation.

Product Mechanism

CX-5461 is a small molecule that selectively inhibits RNA polymerase I, an enzyme that is responsible for synthesizing ribosomal RNA in cells. By inhibiting RNA polymerase I, CX-5461 disrupts ribosomal RNA synthesis, which is necessary for the growth and survival of cancer cells. This leads to cell death and may slow or halt tumor progression. Additionally, CX-5461 has been shown to induce synthetic lethality in cells with a mutated p53 gene, which may make it an effective treatment for cancers that have this mutation.

Safety

CX-5461 is still being studied in clinical trials, and its safety profile is not well established at this time. However, early studies have shown that CX-5461 can have toxic effects on normal cells in addition to cancer cells. CX-5461 has been shown to cause bone marrow suppression and gastrointestinal toxicity in animal studies, and these effects may translate to humans. Additionally, CX-5461 has been shown to have a narrow therapeutic window, meaning that the difference between a therapeutic dose and a toxic dose is small. As with all medications, the potential benefits must be weighed against the potential risks.

Side Effects

The side effects of CX-5461 are not well established at this time, given that it is still being studied in clinical trials. However, some potential side effects have been observed in preclinical studies. These include bone marrow suppression, gastrointestinal toxicity, and cardiac toxicity. Additionally, CX-5461 has been shown to have a narrow therapeutic window, meaning that dosing must be carefully controlled to avoid toxicity. Future studies will be needed to establish the full range of potential side effects.

Dosing Information

The optimal dosing of CX-5461 has not yet been established, as it is still being studied in clinical trials. However, early studies have suggested that the drug has a narrow therapeutic window, meaning that dosing must be carefully controlled to avoid toxicity. In animal studies, CX-5461 has been administered by intravenous injection, but this may or may not be the optimal route of administration in humans. Future studies will be needed to determine the optimal dosing and route of administration for CX-5461.

Conclusion

RNA Polymerase I Inhibitor II CX-5461 CAS: 1138549-36-6 is a promising new drug that has shown potential as a cancer treatment. Its mechanism of action involves selectively inhibiting RNA polymerase I, which is overexpressed in many types of cancer cells. This disruption of ribosomal RNA synthesis has been shown to cause cancer cell death and may slow or halt tumor progression. CX-5461 has also been shown to induce synthetic lethality in cancer cells with a mutated p53 gene, making it a potential treatment option for these cancers. While CX-5461 is still being studied in clinical trials, it has shown promise in preclinical studies. As with all medications, the potential benefits must be weighed against the potential risks, which include bone marrow suppression, gastrointestinal toxicity, and cardiac toxicity. Future studies will be needed to fully establish the safety and efficacy of CX-5461.

Review
Review

ver_code
1/3
X
Send your message to us
please select your country
  • Afghanistan
  • Aland Islands
  • Albania
  • Algeria
  • American Samoa
  • Andorra
  • Angola
  • Anguilla
  • Antigua and Barbuda
  • Argentina
  • Armenia
  • Aruba
  • Australia
  • Austria
  • Azerbaijan
  • Bahamas
  • Bahrain
  • Bangladesh
  • Barbados
  • Belarus
  • Belgium
  • Belize
  • Benin
  • Bermuda
  • Bhutan
  • Bolivia
  • Bosnia and Herzegovina
  • Botswana
  • Bouvet Island
  • Brazil
  • British Indian Ocean Territory
  • British Virgin Islands
  • Brunei Darussalam
  • Bulgaria
  • Burkina Faso
  • Burundi
  • Cambodia
  • Cameroon
  • Canada
  • Cape Verde
  • Caribbean Netherlands
  • Cayman Islands
  • Central African Republic
  • Chad
  • Chile
  • China
  • Christmas Island
  • Cocos Islands
  • Colombia
  • Comoros
  • Congo
  • Cook Islands
  • Costa Rica
  • Cote D'ivoire
  • Cuba
  • Curaçao
  • Cyprus
  • Czech Republic
  • Democratic People's Republic of Korea
  • Democratic Republic of the Congo
  • Denmark
  • Djibouti
  • Dominica
  • East Timor
  • Ecuador
  • Egypt
  • El Salvador
  • Equatorial Guinea
  • Eritrea
  • Estonia
  • Ethiopia
  • Falkland Islands
  • Faroe Islands
  • Fiji
  • Finland
  • France
  • French Guiana
  • French Polynesia
  • French Southern Territories
  • Gabon
  • Gambia
  • Georgia
  • Germany
  • Ghana
  • Gibraltar
  • Greece
  • Greenland
  • Grenada
  • Guadeloupe
  • Guam
  • Guatemala
  • Guernsey
  • Guinea
  • Guinea-Bissau
  • Guyana
  • Haiti
  • Heard Island and Mcdonald Islands
  • Honduras
  • Hong Kong, China
  • Hungary
  • Iceland
  • India
  • Indonesia
  • Iran
  • Iraq
  • Ireland
  • Isle of Man
  • Israel
  • Italy
  • Jamaica
  • Japan
  • Jordan
  • Kazakhstan
  • Kenya
  • Kiribati
  • Korea
  • Kosovo
  • Kuwait
  • Kyrgyzstan
  • Laos
  • Latvia
  • Lebanon
  • Lesotho
  • Liberia
  • Liechtenstein
  • Lithuania
  • Luxembourg
  • Macau, China
  • Macedonia
  • Madagascar
  • Malawi
  • Malaysia
  • Maldives
  • Mali
  • Malta
  • Marshall Islands
  • Martinique
  • Mauritania
  • Mauritius
  • Mayotte
  • Mexico
  • Micronesia
  • Moldova
  • Monaco
  • Mongolia
  • Montenegro
  • Montserrat
  • Morocco
  • Mozambique
  • Myanmar
  • Namibia
  • Nauru
  • Nepal
  • Netherlands
  • Netherlands Antilles
  • New Caledonia
  • New Zealand
  • Nicaragua
  • Niger
  • Nigeria
  • Niue
  • Norfolk Island
  • Northern Mariana Islands
  • Norway
  • Oman
  • Pakistan
  • Palau
  • Palestine
  • Panama
  • Papua New Guinea
  • Paraguay
  • Peru
  • Philippines
  • Pitcairn Islands
  • Poland
  • Portugal
  • Puerto Rico
  • Qatar
  • Reunion
  • Romania
  • Russia
  • Rwanda
  • Saint Barthélemy
  • Saint Helena
  • Saint Kitts and Nevis
  • Saint Lucia
  • Saint Martin
  • Saint Pierre and Miquelon
  • Saint Vincent and the Grenadines
  • San Marino
  • Sao Tome and Principe
  • Saudi Arabia
  • Senegal
  • Serbia
  • Seychelles
  • Sierra Leone
  • Singapore
  • Sint Maarten
  • Slovakia
  • Slovenia
  • Solomon Islands
  • Somalia
  • South Africa
  • South Georgia and The South Sandwich Islands
  • Spain
  • Sri Lanka
  • State of Libya
  • Sudan
  • Suriname
  • Svalbard and Jan Mayen
  • Swaziland
  • Sweden
  • Switzerland
  • Syrian Arab Republic
  • TaiWan, China
  • Tajikistan
  • Tanzania
  • Thailand
  • The Republic of Croatia
  • Togo
  • Tokelau
  • Tonga
  • Trinidad and Tobago
  • Tunisia
  • Turkey
  • Turkmenistan
  • Turks and Caicos Islands
  • Tuvalu
  • Uganda
  • Ukraine
  • United Arab Emirates
  • United Kingdom
  • United States
  • United States Minor Outlying Islands
  • Uruguay
  • US Virgin Islands
  • Uzbekistan
  • Vanuatu
  • Vatican City State
  • Venezuela
  • Vietnam
  • Wallis and Futuna Islands
  • Western Sahara
  • Western Samoa
  • Yemen
  • Zambia
  • Zimbabwe
ver_code